4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-25-083033
Chief Commercial Officer sold 146 shares at $13.35 ($1,949)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna Chief Commercial Officer | 2025-06-05 | Sale 10b5-1 | −146 | $13.35 | $1,949 | 95,911 | D |
| Open-market sales · 146 sh · avg $13.35 · $1,949 | |||||||
Loading xslF345X05/ownership.xml…